ITP may lead to thrombocytopenia in newborns
Like FNAIT, maternal immune thrombocytopenic purpura (ITP) can lead to thrombocytopenia in newborns, according to a recent study.
Like FNAIT, maternal immune thrombocytopenic purpura (ITP) can lead to thrombocytopenia in newborns, according to a recent study.
A newborn was diagnosed with Babesiosis after showing symptoms that could also be explained by an FNAIT diagnosis.
A prospective study aiming to analyze the risk of FNAIT among different ethnic groups is expected to begin soon.
The molecular properties of nipocalimab determine its ability for preventing FNAIT without compromising other immune functions.
Neonatal intraventricular hemorrhage, a potential FNAIT complication, is most frequent six hours after birth in preterm infants.
A new Phase II clinical trial investigating the experimental RLY212 in pregnant patients at risk of FNAIT has recently begun.
A Phase 3 clinical trial aiming to assess the safety and efficacy of nipocalimab in pregnancies at risk of FNAIT is set to begin soon.
In a recent study, Rallybio’s new therapy, RLYB212, successfully prevented fetal and neonatal alloimmune thrombocytopenia in mice.
The distinct patterns of perinatal intracranial hemorrhage (pIH), a feared FNAIT complication, were detailed in a recent study.
A Phase 2 clinical trial for an experimental treatment for FNAIT was recently approved by the European Medicines Agency.